We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.64 | 18.23% | 4.15 | 3.50 | 4.80 | - | 423,867 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/3/2024 06:58 | Sunny San Diego would be lovely wouldn't it right now?A portacabin in Peckham might be a better use of the company's resources. | canaletto | |
29/2/2024 21:57 | looking to book your flight to San Diego already Canaletto? | elpirata | |
29/2/2024 21:52 | AGM is when please Gentlemen? | canaletto | |
29/2/2024 20:06 | Beaches,weather,bars | peverill | |
29/2/2024 19:39 | Im sure the CEO is hard at it, there cant be that much else to do in San Diego California surely | elpirata | |
29/2/2024 14:14 | Is Mrs S still about,if so,wtf is she doing,4 years in,£1m in wages and SFA in return. | peverill | |
29/2/2024 09:35 | Oh No. Not a whisper. | dominiccummings | |
29/2/2024 07:54 | Indeed, not that he's one to mention it, of course. | james japp | |
29/2/2024 06:22 | Dominic even | canaletto | |
29/2/2024 06:21 | A first no less James | canaletto | |
28/2/2024 18:24 | Aaaah. I guess you need a Cambridge Degree to understand it. | dominiccummings | |
28/2/2024 18:21 | Yes, I agree. I wonder who he was known as. My earlier post was written to be sarcastic. | goatherd | |
28/2/2024 17:16 | #92740 I do believe that James Japp enjoyed lives on these threads long long before... | dominiccummings | |
28/2/2024 16:39 | I am certainly very open-minded, Richard. | jeffian | |
28/2/2024 16:30 | Don't you? | goatherd | |
28/2/2024 16:28 | I rather enjoyed "Category Uncertain". Sounds as if I swing both ways. | jeffian | |
28/2/2024 16:28 | Impressive stuff, seeing that post was 16 years before you joined advfn. | goatherd | |
28/2/2024 08:53 | It hit bottom a year or so ago and I am waiting for 'the bounce'. | dominiccummings | |
28/2/2024 05:24 | How is your investment here doing???? | peverill | |
27/2/2024 20:58 | Anything working out for us this decade guys? | dominiccummings | |
27/2/2024 14:05 | I wonder how this is working out? 7 years old today. bluemango 27 Feb '17 - 16:29 - 68648 of 92734 0 5 0 From the interim report, as now confirmed by pools2 above. "As communicated in the recent trading update, launch of the CE marked stroke diagnostic is now scheduled for the second half of 2017 to allow the incorporation of a new class of antibodies generated during the first half by Randox. These antibodies have been validated against all the stroke marker proteins covered by our IP and of interest for this diagnostic, and they deliver significantly improved assay sensitivity" Note full "CE marked assay" launch this H2, not just the research product. | james japp | |
27/2/2024 11:19 | "there is little or no appetite for this" Absolutely. Agree 100%. So the logical response would be to: 1. Ignore it, forget it, or .. 2. Inject a bit of humour Peverill does neither of those. Instead he just boringly, repetitively, tediously, sits here moaning. Like a child you're babysitting and wish you weren't. (No offence) What's the point? That's all. | bluemango | |
27/2/2024 11:07 | There has been one trade today, 2000 @4.27p, there were no trades yesterday. The last post prior to 92730 was 4 days ago, again from the same poster. I think it is fair to 'say' that there is little or no appetite for this bombed out failure and quite right too. | james japp |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions